Results 21 to 30 of about 133,754 (301)

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

BMC Cancer, 2021
Background The current management guidelines recommend that patients with borderline resectable pancreatic adenocarcinoma (BRPC) should initially receive neoadjuvant chemotherapy.
Salvatore Paiella, Giuseppe Malleo, Nicola Simoni, Renato Micera, Stefania Guariglia, Carlo Cavedon, Giovanni Marchegiani, Alessandro Esposito, Luca Landoni, Luca Casetti, Massimiliano Tuveri, Michele Milella, Erica Secchettin, Gessica Manzini, Chiara Bovo, Matteo De Pastena, Martina Fontana, Roberto Salvia, Renzo Mazzarotto, Claudio Bassi   +19 more
doaj   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Arnold, Dirk, Brenner, Baruch, Galle, Peter R., Gockel, Ines, Klautke, Gunther, Lang, Hauke, Möhler, Markus, Roessler, Hans-Peter, Rödel, Claus, Schimanski, Carl Christoph, Schmidberger, Heinz, Thomaidis, Thomas, Trarbach, Tanja   +12 more
core   +1 more source

Current status of total neoadjuvant therapy for locally advanced rectal cancer [PDF]

Asia-Pacific Journal of Clinical Oncology, 2021
AbstractNeoadjuvant chemoradiotherapy (nCRT) plus total mesorectal excision (TME) has been the standard regimen for treatment of patients with locally advanced rectal cancer (LARC), because it significantly reduces the rate of local recurrence and enables sphincter preservation. However, distant metastasis remains the major reason for treatment failure,
Wei Feng, Bin Yu, Zhenya Zhang, Juan Li, Yuxiang Wang   +4 more
openaire   +2 more sources

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer

Life, 2022
In estrogen receptor (ER)-positive breast cancer, changes in biomarker expression after neoadjuvant therapy indicate the therapeutic response and are prognostic.
Mengping Long, Chong You, Qianqian Song, Lina X. J. Hu, Zhaorong Guo, Qian Yao, Wei Hou, Wei Sun, Baosheng Liang, Xiao-Hua Zhou, Yiqiang Liu, Taobo Hu   +11 more
doaj   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Total neoadjuvant therapy for rectal cancer: An emerging option [PDF]

Cancer, 2017
The treatment of locally advanced rectal cancer (LARC) has benefited from improved surgical techniques and from the implementation of neoadjuvant chemoradiotherapy (CRT), which have markedly decreased the rates of local recurrence. However, distant metastatic disease remains the most significant cause of death for these patients.
Ethan B. Ludmir, Manisha Palta, Christopher G. Willett, Brian G. Czito   +3 more
openaire   +2 more sources

Immunonutrition before esophagectomy: Impact on immune surveillance mechanisms [PDF]

, 2017
Preoperative oral immunonutrition was demonstrated to improve immune response and to decrease the infection rate in patients with cancer. This study aimed to assess how immunonutrition could influence the immune cell response in the mucosal ...
Agostini, Marco, Alfieri, Rita, Cagol, Matteo, Castagliuolo, Ignazio, Castoro, Carlo, Cavallin, Francesco, Fassan, Matteo, Kotsafti, Andromachi, Nardi, Teresa, Pinto, Eleonora, Rugge, Massimo, Scarpa, Marco, Scarpa, Melania   +12 more
core   +1 more source

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer

Frontiers in Oncology, 2022
BackgroundNeoadjuvant therapy is a standard treatment for patients with large, nonmetastatic breast cancer and may allow breast-conserving surgery after tumor downsizing while decreasing the risk of subsequent relapse.
Jinmei Zhou, Jiangling Wu, Jiangling Wu, Xiaopeng Hao, Ping Li, Huiqiang Zhang, Xuexue Wu, Jiaxin Chen, Jiawei Liu, Jinyi Xiao, Shaohua Zhang, Zefei Jiang, Yanlian Yang, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Zhiyuan Hu, Tao Wang   +18 more
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Total neoadjuvant therapy for rectal cancer: a guide for surgeons

Canadian Journal of Surgery, 2023
The modern management of rectal cancers continues to evolve. With the release of data from new landmark randomized controlled trials (RAPIDO, PRODIGE-23), total neoadjuvant therapy (TNT) has moved to the forefront of locally advanced rectal cancer treatment and is considered a standard option in selected patients.
Johnson, Garrett G.R.J., Park, Jason, Helewa, Ramzi M., Goldenberg, Benjamin A., Nashed, Maged, Hyun, Eric   +5 more
openaire   +2 more sources